Publikationen

2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000


2014

Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Martinez-Saguer,I.; Cicardi,M.; Suffritti,C.; Rusicke,E.; Aygoren-Pursun,E.; Stoll,H.; Rossmanith,T.; Feussner,A.; Kalina,U.; Kreuz, W. Transfusion 2014. Vol 54:1552-1561

A review of immune tolerance induction with Haemate P in haemophilia A, Escuriola Ettingshausen C.; Kreuz, W. Haemophilia 2014. Vol. 20: 333-339

Inhibitors in patients with haemophilia A. Kreuz, W.; Ettingshausen, C.E. Thromb. Research 2014. In press


2013

The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture? Ettingshausen,C.E.; Kreuz, W. Haemophilia. 2013 Vol.19: 12-17

Risk of angioedema following invasive or surgical procedures in HAE type I and II--the natural history. Aygoren-Pursun,E.; Martinez,Saguer,I; Kreuz, W.; Klingebiel,T.; Schwabe,D. Allergy 2013.Vol 68: 1034-1039

Inhibitors and prophylaxis in paediatric haemophilia patients: Focus on the German experience. Kurnik,K.; Auerswald,G.; Kreuz, W.Thromb. Res. 2013Risk of angioedema following invasive or surgical procedures in HAE type I and II - the natural history. Aygören-Pürsün E, Martinez Saguer I, Kreuz W., Klingebiel T, Schwabe D. Allergy. 2013 Vol.68: 1034-1039.


2012

Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Kreuz W., Rusicke E, Martinez-Saguer I, Aygören-Pürsün E, Heller C, Klingebiel T. Transfusion. 2012 Vol. 52: 100-107.

Hereditary angioedema (HAE) in children and adolescents--a consensus on therapeutic strategies. Wahn,V.; Aberer,W.; Eberl,W.; Fasshauer,M.; Kuhne,T.; Kurnik,K.; Magerl,M.; Meyer-Olson,D.; Martinez-Saguer,I.; Spath,P.; Staubach-Renz,P.; Kreuz, W. Eur. J. Pediatr. 2012. Vol. 171: 1339-1348


2011

Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH(R)) in 14 patients with severe haemophilia A, Bidlingmaier,C.; Kurnik,K.; Escuriola-Ettingshausen,C.; Jager,R.; Klamroth,R.; Male,C.; Marosi,A.; Nemes,L.; von,Stackelberg A.; Kreuz, W. Haemophilia 2011, Vol. 17: 837-840


2010

Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Martinez-Saguer,I.; Rusicke,E.; Aygoren-Pursun,E.; Heller,C.; Klingebiel,T.; Kreuz, W. Am. J. Obstet. Gynecol. 2010. Vol. 203: 131-137

Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series. Ettingshausen,C.E.; Kreuz, W. Haemophilia 2010. Vol. 16: 90-100

Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Martinez-Saguer,I.; Rusicke,E.; Aygoren-Pursun,E.; von,Hentig N.; Klingebiel,T.; Kreuz, W. Transfusion 2010. Vol. 50: 354-360

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. Iorio,A.; Halimeh,S.; Holzhauer,S.; Goldenberg,N.; Marchesini,E.; Marcucci,M.; Young,G.; Bidlingmaier,C.; Brandao,L.R.; Ettingshausen,C.E.; Gringeri,A.; Kenet,G.; Knofler,R.; Kreuz, W.; Kurnik,K.; Manner,D.; Santagostino,E.; Mannucci,P.M.; Nowak-Gottl,U. J. Throm.Haemost. 2010. Vol.6: 1256-1265

Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, Heller C, Klingebiel T, Kreuz W. Am J Obstet Gynecol. 2010. Vol. 203: 131.e1-7.

HAE international home therapy consensus document. Longhurst,H.J.; Farkas,H.; Craig,T.; Aygoren-Pursun,E.; Bethune,C.; Bjorkander,J.; Bork,K.; Bouillet,L.; Boysen,H.; Bygum,A.; Caballero,T.; Cicardi,M.; Dempster,J.; Gompels,M.; Gooi,J.; Grigoriadou,S.; Huffer,U.; Kreuz, W.; Levi,M.M.; Long,J.; Martinez-Saguer,I.; Raguet,M.; Reshef,A.; Bowen,T.; Zuraw,B. Allergy Asthma. Clin Immunol. 2010. Vol.6: 22

On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience. Aygoren-Pursun,E.; Martinez-Saguer,I.; Rusicke,E.; Klingebiel,T.; Kreuz, W. Allergy Asthma. Clin Immunol. 2010. Vol.6: 21

2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Bowen,T.; Cicardi,M.; Farkas,H.; Bork,K.; Longhurst,H.J.; Zuraw,B.; Aygoeren-Pursun,E.; Craig,T.; Binkley,K.; Hebert,J.; Ritchie,B.; Bouillet,L.; Betschel,S.; Cogar,D.; Dean,J.; Devaraj,R.; Hamed,A.; Kamra,P.; Keith,P.K.; Lacuesta,G.; Leith,E.; Lyons,H.; Mace,S.; Mako,B.; Neurath,D.; Poon,M.C.; Rivard,G.E.; Schellenberg,R.; Rowan,D.; Rowe,A.; Stark,D.; Sur,S.; Tsai,E.; Warrington,R.; Waserman,S.; Ameratunga,R.; Bernstein,J.; Bjorkander,J.; Brosz,K.; Brosz,J.; Bygum,A.; Caballero,T.; Frank,M.; Fust,G.; Harmat,G.; Kanani,A.; Kreuz, W.; Levi,M.; Li,H.; Martinez-Saguer,I.; Moldovan,D.; Nagy,I.; Nielsen,E.W.; Nordenfelt,P.; Reshef,A.; Rusicke,E.; Smith-Foltz,S.; Spath,P.; Varga,L.; Xiang,Z.Y. Allergy Asthma. Clin Immunol. 2010. Vol.6: 24


2009

C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Kreuz W., Martinez-Saguer I, Aygören-Pürsün E, Rusicke E, Heller C, Klingebiel T. Transfusion. 2009. Vol.49: 1987-1995.

Inhibitor treatment by rituximab in congenital haemophilia A - Two case reports, Streif,W.; Escuriola Ettingshausen C.; Linde,R.; Kropshofer,G.; Zimmerhackl,L.B.; Kreuz, W., Haemostaseologie 2009


2008

Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab. Kessel C, Königs C, Linde R, Escuriola-Ettinghausen C, Stoll H, Klingebiel T, Dietrich U, Kreuz W. Mol Immunol. 2008. Vol. 46: 8-15.

Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. Gosswein,T.; Kocot,A.; Emmert,G.; Kreuz, W.; Martinez-Saguer,I.; Aygoren-Pursun,E.; Rusicke,E.; Bork,K.; Oldenburg,J.; Muller,C.R. Cytogenet. Genoma.Res. 2008. Vol.121: 181-188

Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. Klarmann,D.; Martinez,Saguer,I; Funk,M.B.; Knoefler,R.; von,Hentig N.; Heller,C.; Kreuz, W. Haemophilia 2008. Vol. 14: 44-49

Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Bowen,T.; Cicardi,M.; Bork,K.; Zuraw,B.; Frank,M.; Ritchie,B.; Farkas,H.; Varga,L.; Zingale,L.C.; Binkley,K.; Wagner,E.; Adomaitis,P.; Brosz,K.; Burnham,J.; Warrington,R.; Kalicinsky,C.; Mace,S.; McCusker,C.; Schellenberg,R.; Celeste,L. Hebert,J.; Valentine,K.; Poon,M.C.; Serushago,B.; Neurath,D.; Yang,W.; Lacuesta,G.; Issekutz,A.; Hamed,A.; Kamra,P.; Dean,J.; Kanani,A.; Stark,D.; Rivard,G.E.; Leith,E.; Tsai,E.; Waserman,S.; Keith,P.K.; Page,D.; Marchesin,S.; Longhurst,H.J.; Kreuz, W.; Rusicke,E.; Martinez-Saguer,I.; Aygoren-Pursun,E.; Harmat,G.; Fust,G.; Li,H.; Bouillet,L.; Caballero,T.; Moldovan,D.; Spath,P.J.; Smith-Foltz,S.; Nagy,I.; Nielsen,E.W.; Bucher,C.; Nordenfelt,P. Ann. Allergy Asthma Immunol. 2008. Vol. 100: S30-S40


2007

Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children--results of a multicenter studys. Kurnik,K.; Kreuz, W.; Horneff,S.; During,C.; Schobess,R.; Bidlingmaier,C.; Ettingshausen,C.E.; Krumpel,A.; Bogdanova,N.; Nowak-Gottl,U. Haematologica 2007. Vol. 92: 982-985

Retrochorionic hematoma in congenital afibrinogenemia: resolution with fibrinogen concentrate infusions. Aygoren-Pursun,E.; Martinez,Saguer,I; Rusicke,E.; Louwen,F.; Geka,F.; Ivaskevicius,V.; Oldenburg,J.; Klingebiel,T.; Kreuz, W. Am. J. Hematol. 2007. Vol. 82: 317-320


2006

Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Ettingshausen,C.E.; Kreuz, W. Haemophilia 2006. Vol. 12: 102-106

Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. von,Hentig N.; Koenigs,C.; Elanjikal,S.; Linde,R.; Dunsch,D.; Kreuz, W.; Funk,M.B. Eur. J. Med. Res. 2006. Vol. 11: 377-380

Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A. Bassus,S.; Wegert,W.; Krause,M.; Escuriola-Ettinghausen,C.; Siegemund,A.; Petros,S.; Scholz,T.; Scharrer,I.; Kreuz, W.; Engelmann,L.; Kirchmaier,C.M. Platelets 2006. Vol. 17: 378-384


2005

Role of von Willebrand factor in immune tolerance induction. Ettingshausen,C.E.; Kreuz, W. Blood Coagul. Fibrinolysis 2005. Vol. 16: S27-S31

Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children. Funk MB, Notheis G, Schuster T, Elanjkal Z, von Hentig N, Stürmer M, Linde R, Dunsch D, Königs C, Wintergerst U, Kreuz W. Eur J Med Res. 2005. Vol. 10: 503-508.


2004

Long-term aspects of hemophilia B treatment: part I-role for prophylaxis. Ettingshausen,C.E.; Kreuz, W. Blood Coagul. Fibrinolysis 2004. Vol. 15: S11-S13

Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. Bowen,T.; Cicardi,M.; Farkas,H.; Bork,K.; Kreuz, W.; Zingale,L.; Varga,L.; Martinez-Saguer,I.; Aygoren-Pursun,E.; Binkley,K.; Zuraw,B.; Davis,A.,III; Hebert,J.; Ritchie,B.; Burnham,J.; Castaldo,A.; Menendez,A.; Nagy,I.; Harmat,G.; Bucher,C.; Lacuesta,G.; Issekutz,A.; Warrington,R.; Yang,W.; Dean,J.; Kanani,A.; Stark,D.; McCusker,C.; Wagner,E.; Rivard,G.E.; Leith,E.; Tsai,E.; MacSween,M.; Lyanga,J.; Serushago,B.; Leznoff,A.; Waserman,S.; de,Serres J. J. Allergy Clin. Immunol. 2004. Vol. 114: 629-637

Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. Agostoni,A.; Aygoren-Pursun,E.; Binkley,K.E.; Blanch,A.; Bork,K.; Bouillet,L.; Bucher,C.; Castaldo,A.J.; Cicardi,M.; Davis,A.E.; De,Carolis C.; Drouet,C.; Duponchel,C.; Farkas,H.; Fay,K.; Fekete,B.; Fischer,B.; Fontana,L.; Fust,G.; Giacomelli,R.; Groner,A.; Hack,C.E.; Harmat,G.; Jakenfelds,J. Juers,M.; Kalmar,L.; Kaposi,P.N.; Karadi,I.; Kitzinger,A.; Kollar,T.; Kreuz, W.; Lakatos,P.; Longhurst,H.J.; Lopez-Trascasa,M.; Martinez-Saguer,I.; Monnier,N.; Nagy,I.; Nemeth,E.; Nielsen,E.W.; Nuijens,J.H.; O'grady,C.; Pappalardo,E.; Penna,V. Juers,M.; Kalmar,L.; Kaposi,P.N.; Karadi,I.; Kitzinger,A.; Kollar,T.; Kreuz, W.; Lakatos,P.; Longhurst,H.J.; Lopez-Trascasa,M.; Martinez-Saguer,I.; Monnier,N.; Nagy,I.; Nemeth,E.; Nielsen,E.W.; Nuijens,J.H.; O'grady,C.; J. Allergy Clin. Immunol. 2004. Vol.114: 51-131


2003

Epidemiology of inhibitors and current treatment strategies. Kreuz W., Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, Heller C, Klarmann D, Klingebiel T; GTH PUP Study Group. Haematologica. 2003 Jun;88(6):EREP04. Review.

Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations? Nowak-Gottl,U.; Escuriola,C.; Kurnik,K.; Schobess,R.; Horneff,S.; Kosch,A.; Kreuz, W.; Pollmann,H. Haemostaseologie 2003. Vol. 23: 36-40


2002

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Kreuz, W.; Ettingshausen,C.E.; Zyschka,A.; Oldenburg,J.; Saguer,I.M.; Ehrenforth,S.; Klingebiel,T. Semin. Thromb. Hemost. 2002. Vol. 28: 285-290

Catheter-related thrombosis in children with hemophilia A: evidence of a multifactorial disease. Ettingshausen,C.E.; Kurnik,K.; Schobess,R.; Kreuz, W.; Halimeh,S.; Pollman,H.; Nowak-Gottl,U. Blood 2002. Vol. 99: 1499-1500

Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Funk,M.B.; Schmidt,H.; Becker,S.; Escuriola,C.; Klarmann,D.; Klingebiel,T.; Kreuz, W.Haemophilia 2002. Vol. 8: 98-103


2001

Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy. Linde,R.; Funk,M.B.; Schuster,T.; Wintergerst,U.; Notheis,G.; Klingebiel,T.; Kreuz, W. AIDS 2001. Vol. 15: 1077-1079

Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Escuriola,Ettingshausen C.; Halimeh,S.; Kurnik,K.; Schobess,R.; Wermes,C.; Junker,R.; Kreuz, W.; Pollmann,H.; Nowak-Gottl,U. Thromb. Haemost 2001. Vol. 85: 218-220


2000

Nelfinavir pharmacokinetics in HIV-infected children: a comparison of twice daily and three times daily dosing. Schuster,T.; Linde,R.; Wintergerst,U.; Funk,M.B.; Kurowski,M.; Kreuz, W.; Hofmann,D. AIDS 2000. Vol. 14: 1466-1468

Is recombinant tissue plasminogen activator an option in the treatment of meningococcus-induced purpura? Veldman, A.; Ehrenberg,A.; Jager,G.; Ettingshausen,C.E.; Schneider,W.; Kreuz, W. Crit Care Med. 2000. Vol. 28: 598-600

Labor
...unser Gerinnungslabor
Anfahrt & Kontakt
...der Weg zu uns

News & Press

 

Publikationen

Hier finden Sie die Publikationen.